FIMECS Appoints Dr. Kanae Gamo as Chief Scientific Officer
News release Download PDF
Kanagawa, Japan, 1, Jan 2021 – FIMECS, Inc. (“FIMECS”) a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Kanae Gamo, Ph.D. to the role of Chief Scientific Officer. Dr. Gamo has strongly led overall biology of FIMECS as a VP Biology based on more than 10 years industry experiences. Her promotion will contribute to progress the development of degrader drugs. Yusuke Tominari, Ph.D., Chief Executive Officer and former Chief Scientific Officer will concentrate to the role of Chief Executive Officer.
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.
# # #
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan